AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 152 min read$BLSM

BlossomHill's BH-30643 Shows 45% Response In EGFR C797S NSCLC; Stock Up

BlossomHill Therapeutics (BLSM) presented Phase 1/2 trial data showing its drug BH-30643 achieved a 45% response rate in EGFR C797S-positive NSCLC patients. The stock rose 6% following the announcement. The drug has FDA Fast Track designation, and experts note its potential for addressing treatment-resistant mutations.

Original reporting
rttnews.com
Published Sep 15, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 4:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BlossomHill's BH-30643 Shows 45% Response In EGFR C797S NSCLC; Stock Up — source image
Source · rttnews.com
Decision brief

The 30-second read

$BLSMBullishHigh
01

Why it matters

The 45% objective response rate and Fast Track designation provide a catalyst for short‑term price appreciation and may attract additional investor interest.

02

Market read

First‑time disclosure of pivotal trial data and regulatory Fast Track status creates a high‑impact, time‑sensitive trading opportunity for BLSM.

03

What to watch

Small patient cohort and short follow‑up; regulatory approval still uncertain beyond Fast Track.

Relevance 9/10Novelty 8/10Timing: pre‑market today

Background

BlossomHill Therapeutics (BLSM) is a clinical‑stage biotech focused on EGFR‑mutant lung cancer. The company presented new data at the IASLC 2026 conference in Seoul.

Company-level read

Ticker impact

$BLSMBullishHigh confidence
Context

Phase 1/2 SOLARA trial of BH-30643 reported 45% response rate and Fast Track designation, driving a 6% pre‑market price rise.

Expected impact

Potential further intraday rally; watch for follow‑on coverage and possible entry on pull‑back.

Evidence & confidence

First disclosure of pivotal trial results and FDA Fast Track status for a biotech with no approved therapy in this indication.

Market effects

Sector

Strengthens the EGFR‑targeted oncology niche and may lift peer biotech valuations.

Regional

Positive for US biotech sector; limited immediate global effect.

Global

Highlights ongoing demand for resistance‑overcoming cancer therapies.

Counterpoint

What could challenge this read

Early‑stage data can be misleading; efficacy may not translate to later phases, risk of over‑optimism.

Key entities

  • company
    BlossomHill Therapeutics Inc.

    US‑listed biotech developing BH-30643 for EGFR C797S‑positive NSCLC.

  • event
    IASLC 2026 World Conference on Lung Cancer

    Venue where the trial data were presented.

Read at source← All news

Related articles

SEP 15
$BLSMHighAI 8/10

Why is BlossomHill Therapeutics stock rallying today?

BlossomHill Therapeutics (BLSM) stock rose 4.4% in pre-market trading after presenting positive Phase 1/2 trial data for BH-30643 at a lung cancer conference. The drug showed a 45% response rate in treatment-resistant patients. CEO J. Jean Cui also presented at an investment conference, and Guggenheim initiated coverage with a Buy rating and $30 price target. The stock is near its 52-week high of $23.37.

investing.com2 min
SEP 15
$BLSMMedAI 8/10

BlossomHill To Present Updated SOLARA Data On BH-30643 In EGFR-Mutant Lung Cancer Today; Stock Up

BlossomHill Therapeutics (BLSM) will present updated Phase 1/2 SOLARA trial data on BH-30643, an investigational EGFR inhibitor, for EGFR-mutant NSCLC with C797S resistance at the 2026 World Conference on Lung Cancer. The FDA granted Fast Track designation to BH-30643 for this indication. The stock rose 4.22% to $21.74 on Monday and is up 6.62% in pre-market trading.

rttnews.com2 min
AUG 31
$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

rttnews.com2 min
AUG 28
$NEOHighAI 8/10

Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

rttnews.com4 min
AUG 18
$BLSMMedAI 8/10

BlossomHill Wins FDA Fast Track For BH-30643 In EGFR-Mutant NSCLC;Stock Up

BlossomHill Therapeutics (BLSM) said the FDA granted Fast Track designation to its investigational OMNI-EGFR inhibitor BH-30643 for adults with advanced or metastatic EGFR C797S-positive NSCLC after prior third-generation EGFR TKI therapy. The company noted Fast Track may enable more frequent FDA interactions and rolling NDA review. BH-30643 is in a Phase 1/2 SOLARA trial. BLSM shares rose to $16.38.

rttnews.com4 min
AUG 18
$BLSMMedAI 8/10

BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

BlossomHill Therapeutics (Nasdaq: BLSM) said the FDA granted Fast Track designation to BH-30643 for advanced or metastatic EGFR C797S-positive NSCLC after prior third-generation EGFR TKI treatment. BH-30643 is in the SOLARA Phase 1/2 first-in-human trial (NCT06706076) across 40+ sites in 10 countries.

finanznachrichten.de4 min